Ashley N. Siverly

974 citations
3 papers · 637 indexed · 1 hit paper · h-index 3
Topics
RNA modifications and cancer (2 papers)RNA Research and Splicing (2 papers)MicroRNA in disease regulation (1 paper)
Partner nations
United StatesChinaTaiwan

In The Last Decade

Ashley N. Siverly

3 papers receiving 634 citations

Hit Papers

Long noncoding RNA MALAT1 suppresses breast cancer metast...20182026202020232018100200300400500

Peers

Ashley N. Siverly
Comparison fields: 5 of 49
  • Molecular Biology 564
  • Cancer Research 553
  • Oncology 38
  • Pulmonary and Respiratory Medicine 30
  • Epidemiology 30
Replace Zilong You with:
Zilong You China
Wang Hu China
Wenjie Jiao China
Xinhong Pei China
Miao Chen China
Dominik Jungen Germany
Zhining Fan China
Ashley N. Siverly relative to Zilong You China Zilong You's profile →
Citations per field
00.5×1.5×2.5×
Zilong You · 1×
Citations per year

Countries citing papers authored by Ashley N. Siverly

Since Specialization
Citations

This map shows the geographic impact of Ashley N. Siverly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashley N. Siverly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashley N. Siverly more than expected).

Fields of papers citing papers by Ashley N. Siverly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashley N. Siverly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashley N. Siverly. The network helps show where Ashley N. Siverly may publish in the future.

Co-authorship network of co-authors of Ashley N. Siverly

This figure shows the co-authorship network connecting the top 25 collaborators of Ashley N. Siverly. A scholar is included among the top collaborators of Ashley N. Siverly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashley N. Siverly. Ashley N. Siverly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

3 of 3 papers shown
#WorkIndexed citations
1
USP37 is a SNAI1 deubiquitinase.
13
2
Long noncoding RNA MALAT1 suppresses breast cancer metastasisbreakdown →
546
3 78

About Ashley N. Siverly

Ashley N. Siverly is a scholar working on Cancer Research, Molecular Biology and Oncology, having authored 3 papers that have together received 637 indexed citations. Recurring topics across this work include RNA modifications and cancer (2 papers), RNA Research and Splicing (2 papers) and MicroRNA in disease regulation (1 paper). The work is most often cited by research in Cancer Research (553 citations), Molecular Biology (564 citations) and Oncology (38 citations). Ashley N. Siverly has collaborated with scholars based in United States, China and Taiwan. Frequent co-authors include Li Ma, Jongchan Kim, Yutong Sun, Han Liang, M. James You, Yumeng Wang, Hyemin Lee, Boyi Gan, Zhenna Xiao and Fan Yao. Their work appears in journals such as Nature Genetics, Cancer Research and PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026